From the Journals

ASCO issues guideline for early detection, management of colorectal cancer


 

FROM THE JOURNAL OF GLOBAL ONCOLOGY

The American Society of Clinical Oncology has issued a new guideline on the early detection and management of colorectal cancer in people at average risk for colorectal cancer, which was written by Gilberto Lopes, MD, of the University of Miami and his associates on an ASCO expert panel.

The panel assembled by ASCO to write the guideline consisted of medical oncology, surgical oncology, surgery, gastroenterology, health technology assessment, cancer epidemiology, pathology, radiology, radiation oncology, and patient advocacy experts. Guidelines from eight different developers were examined, and recommendations from those guidelines were adapted to form the new ASCO guideline. The guideline was published in the Journal of Global Oncology.

In people who are asymptomatic, are aged 50-75 years, have no family history of colorectal cancer, are at average risk, and are in settings with high incidences of colorectal cancer, the expert panel recommends guaiac fecal occult blood test or fecal immunochemical testing every 1-2 years, flexible sigmoidoscopy every 5 years, a combination of flexible sigmoidoscopy every 10 years and annual stool-based testing, or colonoscopy every 10 years, depending on available resources. The testing strategy for those with positive stool-based testing or flexible sigmoidoscopy is colonoscopy or a double-contrast barium enema if colonoscopy is unavailable.

For patients who have polyps, polypectomy at the time of colonoscopy is recommended, with the option of referral for surgical resection if not suitable for endoscopic resection. When symptoms (iron-deficiency anemia, bleeding, abdominal pain, and/or change in bowel habits) are present, a colonoscopy should be performed if available. If colonoscopy is contraindicated, a double-contrast barium enema can be performed; if endoscopy is contraindicated, CT colonography can be performed.

More information, including a data supplement with additional evidence tables, a methodology supplement with information about evidence quality and strength of recommendations, slide sets, and clinical tools and resources is available at www.asco.org/resource-stratified-guidelines, the guideline noted.

Several members of the expert panel reported conflicts of interest.

SOURCE: Lopes G et al. J Glob Oncol. 2019 Feb 25. doi: 10.1200/JGO.18.00213.

This story was updated on March 4, 2019.

Recommended Reading

Positive FIT test should prompt colonoscopy
MDedge Family Medicine
Herpes zoster could pose special threat to younger IBD patients
MDedge Family Medicine
DAAs reduce mortality, cancer risk in HCV study
MDedge Family Medicine
Acceptance and commitment therapy reduced IBD stress, depression
MDedge Family Medicine
Survey: Reproductive counseling is often MIA in IBD
MDedge Family Medicine
Delays of 1-2+ years in IBD diagnosis are common, patients say
MDedge Family Medicine
Enterovirus in at-risk children associated with later celiac disease
MDedge Family Medicine
Cochrane/IBD review roundup: Limited evidence keeps verdicts at bay
MDedge Family Medicine
AGA Clinical Practice Update: Changing utility of serology and histologic measures in celiac disease
MDedge Family Medicine
Experts: Consider enteral therapy in CD, with caveats
MDedge Family Medicine